Publication | Closed Access

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

Rheumatoid DisorderRheumatologyAnti-inflammatoryRheumatic DiseasesDisease-modifying Anti-rheumatic DrugsPharmacologyClinical TrialsInflammatory Rheumatic DiseasePharmacotherapyMedicineRheumatoid ArthritisPhase 3